U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Large Cell Neuroendocrine Carcinoma

MedGen UID:
1791077
•Concept ID:
C5554636
•
Neoplastic Process

Definition

Large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.
Xia L, Wang L, Zhou Z, Han S
Sci Rep 2022 Oct 4;12(1):16562. doi: 10.1038/s41598-022-18421-3. PMID: 36195623Free PMC Article
Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis.
Limonnik V, Abel S, Finley GG, Long GS, Wegner RE
Lung Cancer 2020 Dec;150:107-113. Epub 2020 Oct 6 doi: 10.1016/j.lungcan.2020.10.001. PMID: 33126090

Recent clinical studies

Etiology

Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.
Xia L, Wang L, Zhou Z, Han S
Sci Rep 2022 Oct 4;12(1):16562. doi: 10.1038/s41598-022-18421-3. PMID: 36195623Free PMC Article
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N
Clin Lung Cancer 2021 Jul;22(4):282-291.e6. Epub 2021 Feb 8 doi: 10.1016/j.cllc.2021.02.003. PMID: 33722498
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K
J Thorac Oncol 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989. PMID: 23774385
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T
Jpn J Clin Oncol 2011 Jul;41(7):897-901. Epub 2011 Jun 2 doi: 10.1093/jjco/hyr065. PMID: 21636606

Diagnosis

Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.
Xia L, Wang L, Zhou Z, Han S
Sci Rep 2022 Oct 4;12(1):16562. doi: 10.1038/s41598-022-18421-3. PMID: 36195623Free PMC Article
Role of diagnostic laparoscopy in patients with large cell neuroendocrine carcinoma of the ovary with cancerous peritonitis: case report and review of the literature.
Tsuyoshi H, Yashiro K, Yamada S, Yamamoto M, Onuma T, Kurokawa T, Yoshida Y
J Ovarian Res 2019 Oct 15;12(1):95. doi: 10.1186/s13048-019-0571-8. PMID: 31615543Free PMC Article
Large cell neuroendocrine carcinoma of the lung: is it possible to diagnose from biopsy specimens?
Watanabe R, Ito I, Kenmotsu H, Endo M, Yamamoto N, Ohde Y, Kondo H, Nakajima T, Kameya T
Jpn J Clin Oncol 2013 Mar;43(3):294-304. Epub 2013 Feb 3 doi: 10.1093/jjco/hys221. PMID: 23381206
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T
Jpn J Clin Oncol 2011 Jul;41(7):897-901. Epub 2011 Jun 2 doi: 10.1093/jjco/hyr065. PMID: 21636606

Therapy

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N
Clin Lung Cancer 2021 Jul;22(4):282-291.e6. Epub 2021 Feb 8 doi: 10.1016/j.cllc.2021.02.003. PMID: 33722498
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K
J Thorac Oncol 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989. PMID: 23774385
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T
Jpn J Clin Oncol 2011 Jul;41(7):897-901. Epub 2011 Jun 2 doi: 10.1093/jjco/hyr065. PMID: 21636606

Prognosis

Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.
Xia L, Wang L, Zhou Z, Han S
Sci Rep 2022 Oct 4;12(1):16562. doi: 10.1038/s41598-022-18421-3. PMID: 36195623Free PMC Article
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N
Clin Lung Cancer 2021 Jul;22(4):282-291.e6. Epub 2021 Feb 8 doi: 10.1016/j.cllc.2021.02.003. PMID: 33722498
Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis.
Limonnik V, Abel S, Finley GG, Long GS, Wegner RE
Lung Cancer 2020 Dec;150:107-113. Epub 2020 Oct 6 doi: 10.1016/j.lungcan.2020.10.001. PMID: 33126090
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K
J Thorac Oncol 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989. PMID: 23774385

Clinical prediction guides

Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.
Xia L, Wang L, Zhou Z, Han S
Sci Rep 2022 Oct 4;12(1):16562. doi: 10.1038/s41598-022-18421-3. PMID: 36195623Free PMC Article
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N
Clin Lung Cancer 2021 Jul;22(4):282-291.e6. Epub 2021 Feb 8 doi: 10.1016/j.cllc.2021.02.003. PMID: 33722498
Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis.
Limonnik V, Abel S, Finley GG, Long GS, Wegner RE
Lung Cancer 2020 Dec;150:107-113. Epub 2020 Oct 6 doi: 10.1016/j.lungcan.2020.10.001. PMID: 33126090

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...